Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605085 | 0.93 | MRGPRX4 (0.42) | MRGPRX4HPGDPPARDPPARAS1PR4 | |
| SCHEMBL6602658 | 0.92 | HPGD (0.42) | HPGDCREBBPS1PR4GCGRGIPR | |
| SCHEMBL6602333 | 0.91 | HPGD (0.38) | HPGDPPARDPPARACREBBPS1PR4 | |
| SCHEMBL6805998 | 0.88 | HPGD (0.41) | HPGDCREBBPS1PR4GCGRGIPR | |
| SCHEMBL6603655 | 0.87 | HPGD (0.38) | HPGDPPARDPPARACREBBPS1PR4 | |
| SCHEMBL6604189 | 0.87 | MAPT (0.43) | LTB4RHPGDCREBBPS1PR4MAPT | |
| SCHEMBL6607860 | 0.87 | HPGD (0.40) | HPGDCREBBPS1PR4GCGRGIPR | |
| SCHEMBL6604163 | 0.85 | S1PR4 (0.40) | HPGDCREBBPS1PR4GCGRGIPR | |
| SCHEMBL6804785 | 0.84 | TP53 (0.38) | LTB4RHPGDCREBBPS1PR4GCGR | |
| SCHEMBL6601481 | 0.84 | CYP11B1 (0.42) | HPGDCREBBPS1PR4MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | MRGPRX4 2245/4885LTB4R 2554/4885HPGD 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.